RE: RE: RE: RE: RE: RE: RE: BoDUmpolung.......EXCELLENT POST!!!!.....NOW THAT'S SOMETHING TO DISCUSS!!!!
I really couldn't have said it any better myself; although you all know I tried. This post underscores the problems with SSS and summarizes much of what I have been saying for some time.
It also highlights one major reason why I am invested in this company (again....20,000 @
.057 for full disclosure). That reason is the need for a stroke treatment drug. There is literally nothing else out there and if SSS (NTx-265) could prove to be significantly effective then the company will take off. Likewise, if the company could build on what they know from NTx-265 and increase effectiveness (NTx-265"B"?....jokes), then they may really be onto something!
The problem is that it hasn't yet proved to be significantly effective and a move into Phase III will not necessarily prove this. Likewise, the hope that they could reformulate or modify NTx-265 is not very realistic in the short-term. There is a hope though and that's all it really is.